Atypical Endometrial Cells: Significance and Associated Risks

Diagnosis of atypical endometrial cells is of clinical significance as it may indicate the presence of significant uterine disease. In fact, more than one-third of women with histological follow-up have been found to have such conditions. Atypical endometrial cells may be associated with various conditions such as endometrial polyp, chronic endometritis, intrauterine contraceptive device (IUCD), endometrial hyperplasia, and endometrial carcinoma. The risk of carcinoma is particularly concerning, and patients should be referred to a gynaecologist for further investigation. Urgent referral is recommended, and patients should be seen within two weeks of referral to ensure timely diagnosis and treatment.

Understanding Group B Streptococcus (GBS) Infection in Neonates

Group B Streptococcus (GBS) is a common cause of severe infection in newborns during the early stages of life. It is estimated that 20-40% of mothers carry GBS in their bowel flora, making them potential carriers of the bacteria. Infants can be exposed to GBS during labor and delivery, which can lead to serious infections. Prematurity, prolonged rupture of the membranes, previous sibling GBS infection, and maternal pyrexia are all risk factors for GBS infection.

The Royal College of Obstetricians and Gynaecologists (RCOG) has published guidelines on GBS management. The guidelines state that universal screening for GBS should not be offered to all women, and a maternal request is not an indication for screening. Women who have had GBS detected in a previous pregnancy should be informed that their risk of maternal GBS carriage in this pregnancy is 50%. They should be offered intrapartum antibiotic prophylaxis (IAP) or testing in late pregnancy and then antibiotics if still positive. If women are to have swabs for GBS, this should be offered at 35-37 weeks or 3-5 weeks prior to the anticipated delivery date. IAP should be offered to women with a previous baby with early- or late-onset GBS disease, women in preterm labor regardless of their GBS status, and women with a pyrexia during labor (>38ºC). Benzylpenicillin is the antibiotic of choice for GBS prophylaxis.

During the booking visit for prenatal care, healthcare providers typically test for sexually transmitted infections (STIs) that can have serious consequences for the mother and/or the developing fetus. These include syphilis, hepatitis B, and HIV. Testing for hepatitis C is usually only done for women who are at high risk, such as those who use intravenous drugs. Other STIs, such as chlamydia, gonorrhea, trichomonas, bacterial vaginosis, genital herpes, and genital warts, are not routinely tested for during pregnancy unless the patient has symptoms or is considered to be at risk. It is important to identify and treat STIs during pregnancy to prevent adverse outcomes for both the mother and the baby.

Antenatal care is an important aspect of pregnancy, and the National Institute for Health and Care Excellence (NICE) has issued guidelines on routine care for healthy pregnant women. The guidelines recommend 10 antenatal visits for first pregnancies and 7 visits for subsequent pregnancies, provided that the pregnancy is uncomplicated. Women do not need to see a consultant if their pregnancy is uncomplicated.

The timetable for antenatal visits begins with a booking visit between 8-12 weeks, where general information is provided on topics such as diet, alcohol, smoking, folic acid, vitamin D, and antenatal classes. Blood and urine tests are also conducted to check for conditions such as hepatitis B, syphilis, and asymptomatic bacteriuria. An early scan is conducted between 10-13+6 weeks to confirm dates and exclude multiple pregnancies, while Down’s syndrome screening is conducted between 11-13+6 weeks.

At 16 weeks, women receive information on the anomaly and blood results, and if their haemoglobin levels are below 11 g/dl, they may be advised to take iron supplements. Routine care is conducted at 18-20+6 weeks, including an anomaly scan, and at 25, 28, 31, and 34 weeks, where blood pressure, urine dipstick, and symphysis-fundal height (SFH) are checked. Women who are rhesus negative receive anti-D prophylaxis at 28 and 34 weeks.

At 36 weeks, presentation is checked, and external cephalic version may be offered if indicated. Information on breastfeeding, vitamin K, and ‘baby-blues’ is also provided. Routine care is conducted at 38 weeks, and at 40 weeks (for first pregnancies), discussion about options for prolonged pregnancy takes place. At 41 weeks, labour plans and the possibility of induction are discussed. The RCOG advises that either a single-dose or double-dose regime of anti-D prophylaxis can be used, depending on local factors.

Medical Management of Menorrhagia

Menorrhagia is a condition where menstrual loss exceeds 80 ml. While cyclic progestins have been used to treat menorrhagia, they have not been adequately tested in randomized controlled trials. On the other hand, tranexamic acid is considered the most effective medical intervention for menorrhagia.

According to NICE guidelines, if pharmaceutical treatment is appropriate for menorrhagia, hormonal or non-hormonal treatments should be considered in a specific order. The first option is the levonorgestrel-releasing intrauterine system, which provides long-term relief for at least 12 months. The second option is tranexamic acid, non-steroidal anti-inflammatory drugs (NSAIDs), or combined oral contraceptives. The third option is norethisterone (15 mg) daily from days 5 to 26 of the menstrual cycle or injected long-acting progestogens.

If hormonal treatments are not acceptable to the woman, then either tranexamic acid or NSAIDs can be used. It is important to note that a randomized trial of high-dose, longer-term cyclic norethisterone compared with a progestin-releasing IUD showed that flow was reduced by 87%. However, the current consensus of opinion favors tranexamic acid as the most effective medical intervention.

Diagnosis of Gestational Diabetes

Gestational diabetes is a common condition that affects pregnant women. It is important to be familiar with the threshold levels of plasma glucose for diagnosing gestational diabetes using both a fasting and 75g 2-hour oral glucose tolerance test. The diagnosis of gestational diabetes is different from that of non-pregnant or male patients.

To diagnose gestational diabetes, a woman should have either a fasting plasma glucose level of 5.6 mmol/litre or above or a 2-hour plasma glucose level of 7.8 mmol/litre or above. For non-pregnant or male patients, the figures are 7 mmol/l and 11.1 mmol/l.

It is recommended that patients should be offered a 75 g 2-hour OGTT if they have risk factors for diabetes or if they had gestational diabetes in a previous pregnancy. In 2015, NICE offered new advice that glycosuria of 2+ or above on one occasion or of 1+ or above on two or more occasions detected by reagent strip testing during routine antenatal care may indicate undiagnosed gestational diabetes. If this is observed, further testing should be considered to exclude gestational diabetes.

FSH Testing for Women on Contraception

Current guidance from the Faculty for Sexual and Reproductive Healthcare suggests that women using progestogen-only contraception can have their FSH levels measured, but only if they are over 50 years old. However, a single elevated FSH reading is not enough to determine ovarian failure. If FSH levels are consistently above 30, contraception can be stopped after a year. It’s important to note that amenorrhea alone is not a reliable indicator of ovarian failure in women taking exogenous hormones. Additionally, for women using combined hormones, FSH testing during a hormone-free period is not a reliable indicator of ovarian failure. Proper testing and monitoring are crucial for women on contraception to ensure their reproductive health.

Understanding Menarche and Puberty in Girls

Less than 3% of girls experience menarche after the age of 15, which is associated with the deceleration phase of the height velocity curve seen in puberty. The first sign of puberty in girls is breast bud development. However, delayed or absent puberty may indicate an underlying problem. Very high levels of gonadotrophins may suggest ovarian failure, while low levels may indicate a pituitary cause. Understanding the signs and symptoms of puberty can help girls and their families navigate this important stage of development.

Breastfeeding women can safely take SSRIs such as sertraline or paroxetine as the amount of antidepressant passed on to the infant through breast milk is very low and not considered harmful. Therefore, it is recommended that women with postnatal depression continue to breastfeed while receiving antidepressant treatment.

Understanding Postpartum Mental Health Problems

Postpartum mental health problems can range from mild ‘baby-blues’ to severe puerperal psychosis. To screen for depression, healthcare professionals may use the Edinburgh Postnatal Depression Scale, which is a 10-item questionnaire that indicates how the mother has felt over the previous week. A score of over 13 indicates a ‘depressive illness of varying severity’, and the questionnaire includes a question about self-harm. The sensitivity and specificity of this screening tool are over 90%.

‘Baby-blues’ are seen in around 60-70% of women and typically occur 3-7 days following birth. This condition is more common in primips, and mothers are characteristically anxious, tearful, and irritable. Postnatal depression affects around 10% of women, with most cases starting within a month and typically peaking at 3 months. The features of postnatal depression are similar to depression seen in other circumstances.

Puerperal psychosis affects approximately 0.2% of women and usually occurs within the first 2-3 weeks following birth. The features of this condition include severe swings in mood (similar to bipolar disorder) and disordered perception (e.g. auditory hallucinations). Reassurance and support are important for all these conditions, but admission to hospital is usually required for puerperal psychosis, ideally in a Mother & Baby Unit. Cognitive behavioural therapy may be beneficial, and certain SSRIs such as sertraline and paroxetine may be used if symptoms are severe. While these medications are secreted in breast milk, they are not thought to be harmful to the infant. However, fluoxetine is best avoided due to its long half-life. There is around a 25-50% risk of recurrence following future pregnancies.

Having a short inter-pregnancy interval of less than 12 months between childbirth and conceiving again can lead to a higher likelihood of preterm birth, low birthweight, and small for gestational age babies. Women should be informed of this risk, and it is currently recommended by the World Health Organisation to wait at least 24 months after childbirth before getting pregnant again. It is important to note that the risk associated with a short inter-pregnancy interval is still relatively low.

After giving birth, women need to use contraception after 21 days. The Progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first 2 days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the Combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than 6 weeks postpartum. If breastfeeding is between 6 weeks to 6 months postpartum, it is UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk postpartum. After day 21, additional contraception should be used for the first 7 days.

The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after 4 weeks. Meanwhile, the Lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than 6 months postpartum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Folic Acid Requirements for Women During Pregnancy

Most women are advised to take 400 mcg of folic acid daily from before conception until week 12 of pregnancy. However, there are exceptions to this rule. Women who are at a higher risk of neural tube defects, such as those with a history of bearing children with NTDs, or women with diabetes or taking anticonvulsants, should take a higher dose of 5 mg daily from before conception until week 12 of pregnancy.

Another group of women who require a higher dose of folic acid are those with sickle cell disease. They need to take 5 mg of folic acid daily throughout pregnancy, and even when not pregnant, they’ll usually be taking folic acid 5 mg every 1 to 7 days, depending on the severity of their disease. It’s important for women to consult with their healthcare provider to determine the appropriate dose of folic acid for their individual needs during pregnancy.

The BNF recommends against the use of quinolones during pregnancy due to the risk of arthropathy observed in animal studies. While there have been reports of a potential increase in the risk of necrotizing enterocolitis with the use of co-amoxiclav during pregnancy, the evidence is not conclusive. The BNF states that co-amoxiclav is currently considered safe for use during pregnancy, and provides links to both the BNF and the UK teratology information service for further information.

Prescribing Considerations for Pregnant Patients

When it comes to prescribing medication for pregnant patients, it is important to exercise caution as very few drugs are known to be completely safe during pregnancy. Some countries have developed a grading system to help guide healthcare professionals in their decision-making process. It is important to note that the following drugs are known to be harmful and should be avoided: tetracyclines, aminoglycosides, sulphonamides and trimethoprim, quinolones, ACE inhibitors, angiotensin II receptor antagonists, statins, warfarin, sulfonylureas, retinoids (including topical), and cytotoxic agents.

In addition, the majority of antiepileptics, including valproate, carbamazepine, and phenytoin, are potentially harmful. However, the decision to stop such treatments can be difficult as uncontrolled epilepsy poses its own risks. It is important for healthcare professionals to carefully weigh the potential risks and benefits of any medication before prescribing it to a pregnant patient.

Premature Ovarian Insufficiency: Causes, Symptoms, and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flashes, night sweats, infertility, secondary amenorrhoea, and elevated FSH and LH levels. Hormone replacement therapy or a combined oral contraceptive pill is recommended until the age of the average menopause, which is 51 years. It is important to note that HRT doesn’t provide contraception in case spontaneous ovarian activity resumes.

The Mirena®, Levosert®, and Jaydess® are three types of LNG-IUS available in the UK for women. The Mirena® coil can be used for contraception, heavy menstrual bleeding (HMB), and endometrial protection during estrogen-only hormone replacement therapy (HRT) for up to 5 years. Levosert® is licensed for contraception and HMB for 3 years, while Jaydess® is licensed for contraception only for 3 years. However, the faculty of sexual and reproductive health recommends that women aged 45 or over can use Mirena® for contraception until the age of 55, as long as it is not being used for endometrial protection during HRT. Therefore, for a 45-year-old patient, the correct answer is 1.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.

When it comes to treating infertility in PCOS, clomifene is usually the first choice. Metformin can also be used, but only after anti-oestrogens like clomifene have been tried.

Managing Polycystic Ovarian Syndrome

Polycystic ovarian syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. Its management is complex due to the unclear cause of the condition. However, it is known that PCOS is associated with high levels of luteinizing hormone and hyperinsulinemia, and there is some overlap with the metabolic syndrome. General management includes weight reduction if appropriate and the use of combined oral contraceptives (COC) to regulate the menstrual cycle and induce a monthly bleed.

Hirsutism and acne are common symptoms of PCOS, and a COC pill may be used to manage them. Third-generation COCs with fewer androgenic effects or co-cyprindiol with an anti-androgen action are possible options. If these do not work, topical eflornithine may be tried, or spironolactone, flutamide, and finasteride may be used under specialist supervision.

Infertility is another issue that women with PCOS may face. Weight reduction is recommended if appropriate, and the management of infertility should be supervised by a specialist. There is an ongoing debate about whether metformin, clomifene, or a combination should be used to stimulate ovulation. A 2007 trial published in the New England Journal of Medicine suggested that clomifene was the most effective treatment. However, there is a potential risk of multiple pregnancies with anti-oestrogen therapies such as clomifene. The RCOG published an opinion paper in 2008 and concluded that on current evidence, metformin is not a first-line treatment of choice in the management of PCOS. Metformin is also used, either combined with clomifene or alone, particularly in patients who are obese. Gonadotrophins may also be used.

The Caldicott guardian is responsible for safeguarding patient information.

The Role of Caldicott Guardians in Ensuring Patient Data Security

The Caldicott Report of 1997 highlighted the inadequacies in the management of confidential patient data in some parts of the NHS. To address this issue, the report recommended the appointment of Caldicott Guardians, who are responsible for ensuring the security of patient data.

Caldicott Guardians are members of staff who are tasked with overseeing the handling of confidential patient information within their respective NHS organizations. They are responsible for ensuring that patient data is kept secure and that access to it is restricted only to those who have a legitimate need to know.

Today, it is mandatory for every NHS organization to have a Caldicott Guardian. This requirement is in place to ensure that patient data is protected from unauthorized access, theft, or misuse. By appointing Caldicott Guardians, the NHS is taking proactive steps to safeguard the privacy and confidentiality of patient information, which is essential for maintaining trust and confidence in the healthcare system.

Implications of Unintended Pregnancy and Contraceptive Efficacy

The risk of unintended pregnancy varies among different contraceptive methods. The Progestogen implant has the lowest failure rate at 0.05% in the first year of use, while the COCP has a failure rate of 9%. However, the implications of an unintended pregnancy for an individual patient must be considered when advising on contraception. In this case, the patient’s FEV1 and BMI suggest that the consequences of an unintended pregnancy would be very serious.

Furthermore, while the COCP may not be a suitable option for this patient due to its high failure rate, her potential risk factors for developing VTE should also be taken into account. Despite having a negative personal and family history, normotension, non-smoking status, and BMI <30 kg/m2, her frequent hospital admissions and indwelling intravenous catheters may increase her risk of developing VTE. Therefore, careful consideration is necessary when selecting a contraceptive method for this patient.

In the case of treating Chlamydia during pregnancy, erythromycin would be the most appropriate option among the listed antibiotics. Amoxicillin, azithromycin, or erythromycin can be used to treat Chlamydia during pregnancy. However, since the patient is allergic to penicillin, amoxicillin is not suitable. Doxycycline, which is the first-line treatment for uncomplicated Chlamydia in non-pregnant individuals, is not recommended during pregnancy due to its teratogenic effects. Co-amoxiclav is also not appropriate for treating Chlamydia and is contraindicated in this patient due to their penicillin allergy.

Chlamydia is the most common sexually transmitted infection in the UK caused by Chlamydia trachomatis. It is often asymptomatic but can cause cervicitis and dysuria in women and urethral discharge and dysuria in men. Complications include epididymitis, pelvic inflammatory disease, and infertility. Testing is done through nuclear acid amplification tests (NAATs) on urine or swab samples. Screening is recommended for sexually active individuals aged 15-24 years. Doxycycline is the first-line treatment, but azithromycin may be used if contraindicated. Partners should be notified and treated.

Compared to the Mirena IUS, the Jaydess IUS has lower release rates and serum levels of levonorgestrel. In the UK, there are various copper coils available with either banded copper arms or copper in the stem only, licensed for either 5 or 10 years. The insertion tube sizes vary, with the Nova-T 380 being the smallest at 3.6mm and the Mirena and Jaydess at 4.4mm and 3.8mm, respectively. The Jaydess has the lowest levels of levonorgestrel at 13.5mg, while the Kyleena has 19.5mg and the Mirena has 52mg. The Jaydess is licensed for 3 years, while the Mirena and Kyleena are licensed for 5 years.

New intrauterine contraceptive devices include the Jaydess® IUS and Kyleena® IUS. The Jaydess® IUS is licensed for 3 years and has a smaller frame, narrower inserter tube, and less levonorgestrel than the Mirena® coil. The Kyleena® IUS has 19.5mg LNG, is smaller than the Mirena®, and is licensed for 5 years. Both result in lower serum levels of LNG, but the rate of amenorrhoea is less with Kyleena® compared to Mirena®.

Women using oral or topical isotretinoin must take effective contraception as both forms are highly prohibited during pregnancy.

Prescribing Considerations for Pregnant Patients

When it comes to prescribing medication for pregnant patients, it is important to exercise caution as very few drugs are known to be completely safe during pregnancy. Some countries have developed a grading system to help guide healthcare professionals in their decision-making process. It is important to note that the following drugs are known to be harmful and should be avoided: tetracyclines, aminoglycosides, sulphonamides and trimethoprim, quinolones, ACE inhibitors, angiotensin II receptor antagonists, statins, warfarin, sulfonylureas, retinoids (including topical), and cytotoxic agents.

In addition, the majority of antiepileptics, including valproate, carbamazepine, and phenytoin, are potentially harmful. However, the decision to stop such treatments can be difficult as uncontrolled epilepsy poses its own risks. It is important for healthcare professionals to carefully weigh the potential risks and benefits of any medication before prescribing it to a pregnant patient.

Prenatal Screening Tests: An Overview

One of the routine tests offered to pregnant women is the second trimester anomaly scan, which screens for fetal abnormalities. However, for more specific testing, amniocentesis and chorionic villus sampling (CVS) are available. Amniocentesis is typically done between weeks 15-20 of pregnancy and can detect Down’s syndrome, spina bifida, and other conditions. CVS, on the other hand, is done between weeks 10-13 and is only offered to those with a high risk of serious inherited conditions. The first trimester scan is mainly used to confirm and date the pregnancy, while the second trimester anomaly scan is used to detect fetal abnormalities. The nuchal translucency (NT) scan is also offered as part of the NHS screening program between weeks 11-13.6 of pregnancy. It’s important to note that while these tests are available, they are not routinely offered to all women and carry a small risk of miscarriage.

Breastfeeding is generally safe with most anti-epileptic drugs, including the commonly prescribed Lamotrigine. This drug is often preferred for women as it doesn’t affect their ability to bear children. However, Carbimazole and Diazepam’s active metabolite can be passed on to the baby through breast milk and should be avoided. Isotretinoin’s effect on breastfed infants is not well studied, but oral retinoids should generally be avoided while breastfeeding.

Pregnancy and breastfeeding can be a concern for women with epilepsy. It is generally recommended that women continue taking their medication during pregnancy, as the risks of uncontrolled seizures outweigh the potential risks to the fetus. However, it is important to aim for monotherapy and to take folic acid before pregnancy to reduce the risk of neural tube defects. The use of antiepileptic medication during pregnancy can increase the risk of congenital defects, with sodium valproate being associated with neural tube defects, carbamazepine being considered the least teratogenic of the older antiepileptics, and phenytoin being associated with cleft palate. Lamotrigine may be a safer option, but the dose may need to be adjusted during pregnancy. Breastfeeding is generally safe for mothers taking antiepileptics, except for barbiturates. Women taking phenytoin should be given vitamin K in the last month of pregnancy to prevent clotting disorders in the newborn. It is important to seek specialist neurological or psychiatric advice before starting or continuing antiepileptic medication during pregnancy or in women of childbearing age. Recent evidence has shown a significant risk of neurodevelopmental delay in children following maternal use of sodium valproate, leading to recommendations that it should not be used during pregnancy or in women of childbearing age unless absolutely necessary.

Understanding Menopause and Hormone Replacement Therapy

The menopause is a natural biological process that marks the end of a woman’s reproductive years. It is defined as the cessation of normal menstruation, which typically occurs around the age of 51 in the UK. However, the climacteric, a period of gradually declining ovarian function, can begin years before and last years after menopause itself. This perimenopausal period can be characterized by irregular periods and occasional menorrhagia.

To be considered postmenopausal, a woman must have gone without menstruation for at least 12 months. However, it is important to note that a woman can still potentially become pregnant for up to two years after her last period if she is under 50, and one year if over 50. Therefore, contraception should be discussed with healthcare providers.

While hormone replacement therapy (HRT) can be used to alleviate symptoms of hypo-oestrogenism, it is not always necessary or appropriate. Routine hormone testing is not recommended unless there is diagnostic doubt. Women who are considering HRT should discuss the potential risks and benefits with their healthcare provider, as well as any pre-existing medical conditions that may affect their suitability for treatment.

Treatment of C. trachomatis Infection in Pregnancy

C. trachomatis infection is becoming more common in the UK and can lead to adverse fetal outcomes such as spontaneous miscarriage, premature rupture of membranes, and intrauterine growth retardation. Therefore, treatment is advised ahead of test results if chlamydia is strongly suspected clinically. Current UK guidelines recommend three different options for pregnant patients: erythromycin, amoxicillin, and azithromycin. However, erythromycin is the most appropriate option as it is the recommended treatment by most guidelines. Doxycycline, co-trimoxazole, and metronidazole are not routinely used in the treatment of chlamydia during pregnancy. It is also important to note that pregnant patients should be tested for cure 5 weeks after completing treatment (or 6 weeks if azithromycin is used).

Breastfeeding women who follow a vegan diet may require a B12 supplement as this vitamin is primarily present in meat and dairy products. Vegans can obtain vitamin B12 from fortified breakfast cereals and yeast extracts like Marmite. Additionally, the NHS recommends that all breastfeeding women, regardless of their dietary preferences, should take a daily vitamin D supplement of 10 mcg to promote bone health for themselves and their baby. Women who are eligible for Healthy Start vouchers may receive free supplements, and their Health Visitor can provide guidance on this matter.

Vitamin B12 is a type of water-soluble vitamin that belongs to the B complex group. Unlike other vitamins, it can only be found in animal-based foods. The human body typically stores enough vitamin B12 to last for up to 5 years. This vitamin plays a crucial role in various bodily functions, including acting as a cofactor for the conversion of homocysteine into methionine through the enzyme homocysteine methyltransferase, as well as for the isomerization of methylmalonyl CoA to Succinyl Co A via the enzyme methylmalonyl mutase. Additionally, it is used to regenerate folic acid in the body.

However, there are several causes of vitamin B12 deficiency, including pernicious anaemia, Diphyllobothrium latum infection, and Crohn’s disease. When the body lacks vitamin B12, it can lead to macrocytic, megaloblastic anaemia and peripheral neuropathy. To prevent these consequences, it is important to ensure that the body has enough vitamin B12 through a balanced diet or supplements.

If a patient misses a progesterone only pill by over 12 hours or a desogestrel pill by over 36 hours, they should take the missed pill as soon as they remember. Only one pill should be taken, even if multiple pills have been missed. The next pill should be taken at the usual time, which may result in taking two pills in one day. To ensure effectiveness, additional contraceptive precautions such as condoms or abstaining from sex should be taken for 48 hours after restarting the pill. Emergency contraception may be necessary if unprotected sex occurred after the missed pill and within 48 hours of restarting it. The desogestrel pill has the advantage of a longer window for taking it, reducing the likelihood of missed pills.

The progestogen only pill (POP) has simpler rules for missed pills compared to the combined oral contraceptive pill. It is important to not confuse the two. For traditional POPs such as Micronor, Noriday, Norgeston, and Femulen, as well as Cerazette (desogestrel), if a pill is less than 3 hours late, no action is required and pill taking can continue as normal. However, if a pill is more than 3 hours late (i.e. more than 27 hours since the last pill was taken), action is needed. If a pill is less than 12 hours late, no action is required. But if a pill is more than 12 hours late (i.e. more than 36 hours since the last pill was taken), action is needed.

If action is needed, the missed pill should be taken as soon as possible. If more than one pill has been missed, only one pill should be taken. The next pill should be taken at the usual time, which may mean taking two pills in one day. Pill taking should continue with the rest of the pack. Extra precautions, such as using condoms, should be taken until pill taking has been re-established for 48 hours.

Vaccinations for Pregnant Women

It is important to consider the potential risks and benefits of vaccinations for pregnant women. Live virus vaccines, such as the yellow fever vaccine, should not be given to pregnant women due to the theoretical risk of the fetus contracting the infection. However, if travel to a high-risk area is unavoidable, the individual risk from the disease and vaccine should be assessed. Inactivated viral or bacterial vaccines and toxoids, such as those for hepatitis A and B, cholera, and tetanus, are generally safe for pregnant women and may be given when clinically indicated. It is important to consult with a healthcare provider to determine the best course of action for each individual case.

After giving birth, women need to use contraception after 21 days. The Progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first 2 days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the Combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than 6 weeks postpartum. If breastfeeding is between 6 weeks to 6 months postpartum, it is UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk postpartum. After day 21, additional contraception should be used for the first 7 days.

The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after 4 weeks. Meanwhile, the Lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than 6 months postpartum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Investigating Secondary Amenorrhoea with Galactorrhoea

Any patient who presents with secondary amenorrhoea, the absence of menstrual periods for at least three consecutive months, should first have pregnancy ruled out before further investigation. This is because pregnancy can cause secondary amenorrhoea and may also lead to galactorrhoea, the production of breast milk in a non-lactating individual.

If pregnancy is ruled out, the next step is to measure prolactin levels. Hyperprolactinaemia, a condition where there is an excess of prolactin in the blood, can cause both secondary amenorrhoea and galactorrhoea. Further investigation may be necessary to determine the underlying cause of hyperprolactinaemia, which can include pituitary tumors, medication side effects, or other medical conditions.

In summary, investigating secondary amenorrhoea with galactorrhoea requires ruling out pregnancy and measuring prolactin levels to determine the underlying cause of the condition.

According to NICE guidelines, women who are at high risk of VTE and are seeking HRT should be referred to a haematologist before starting any treatment, even if it is transdermal. While the risk of VTE associated with HRT is higher for oral preparations than transdermal ones, the risk for transdermal HRT at standard therapeutic doses is not greater than the baseline risk. However, for women with a significant baseline risk, such as those with a strong family history of VTE or a hereditary thrombophilia, referral to a haematologist for assessment is recommended before considering HRT. Therefore, all options that suggest prescribing HRT are incorrect, with oral prescription being the most problematic. It is not enough to advise this woman to manage her symptoms conservatively, as there is clear guidance to refer her to a specialist for additional help.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progestogen, to alleviate menopausal symptoms. However, this treatment can have side-effects such as nausea, breast tenderness, fluid retention, and weight gain.

Moreover, there are potential complications associated with HRT. One of the most significant risks is an increased likelihood of breast cancer, particularly when a progestogen is added. The Women’s Health Initiative (WHI) study found that the relative risk of developing breast cancer was 1.26 after five years of HRT use. The risk of breast cancer is related to the duration of HRT use, and it begins to decline when the treatment is stopped. Additionally, HRT use can increase the risk of endometrial cancer, which can be reduced but not eliminated by adding a progestogen.

Another potential complication of HRT is an increased risk of venous thromboembolism (VTE), particularly when a progestogen is added. However, transdermal HRT doesn’t appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any HRT treatment, even transdermal. Finally, HRT use can increase the risk of stroke and ischaemic heart disease if taken more than ten years after menopause.

In conclusion, while HRT can be an effective treatment for menopausal symptoms, it is essential to be aware of the potential adverse effects and complications associated with this treatment. Women should discuss the risks and benefits of HRT with their healthcare provider before starting any treatment.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.